Background and purpose: Neuropathic pain affects up to 10% of the global population and is caused by an injury or a disease affecting the somatosensory, peripheral, or central nervous system. NP is characterized by chronic, severe and opioid-resistant properties. Therefore, its clinical management remains very challenging. The N-type voltage-gated calcium channel, Cav 2.2, is a validated target for therapeutic intervention in chronic and neuropathic pain. The conotoxin ziconotide (Prialt®) is an FDA-approved drug that blocks Cav 2.2 channel but needs to be administered intrathecally. Thus, although being principally efficient, the required application route is very much in disfavour.
Experimental approach and key results: Here, we describe an orally available drug candidate, RD2, which competes with ziconotide binding to Cav 2.2 at nanomolar concentrations and inhibits Cav 2.2 almost completely reversible. Other voltage-gated calcium channel subtypes, like Cav 1.2 and Cav 3.2, were affected by RD2 only at concentrations higher than 10 μM. Data from sciatic inflammatory neuritis rat model demonstrated the in vivo proof of concept, as low-dose RD2 (5 mg·kg-1 ) administered orally alleviated neuropathic pain compared with vehicle controls. High-dose RD2 (50 mg·kg-1 ) was necessary to reduce pain sensation in acute thermal response assessed by the tail flick test.
Conclusions and implications: Taken together, these results demonstrate that RD2 has antiallodynic properties. RD2 is orally available, which is the most convenient application form for patients and caregivers. The surprising and novel result from standard receptor screens opens the room for further optimization into new promising drug candidates, which address an unmet medical need.
Keywords: N-type calcium channel; Prialt®; SNX 111; d-enantiomeric peptide; neuropathic pain treatment; ziconotide; ω-Conotoxin MVIIA.
© 2023 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.